

Map and Multiple Cloning Site (MCS) of pTRE-Tight Vector. Unique restriction sites are in bold.

Description

pTRE-Tight is a response plasmid that can be used to express a gene of interest (Gene X) in our Tet-On® and Tet-Off® Gene Expression Systems and Cell Lines (1). The Tet Expression Systems and Cell Lines give researchers ready access to the tetracycline-regulated expression systems described by Gossen & Bujard (2; Tet-Off) and Gossen *et al.* (3; Tet-On). pTRE-Tight contains an MCS immediately downstream of the Tet-responsive P_{tight} promoter. cDNAs or genes inserted into the MCS will be responsive to the tTA and rtTA regulatory proteins in the Tet-Off and Tet-On systems, respectively. P_{tight} contains a modified Tet response element (TRE_{mod}), which consists of seven direct repeats of a 36-bp sequence that contains the 19-bp tet operator sequence (*tetO*). The TRE_{mod} is just upstream of the minimal CMV promoter ($P_{\text{min}CMVA}$), which lacks the enhancer that is part of the complete CMV promoter. Consequently, P_{tight} is silent in the absence of binding of TetR or rTetR to the *tetO* sequences. Note that the cloned insert must have an initiating ATG codon. In some cases, addition of a Kozak consensus ribosome binding site (4) may improve expression levels; however, many cDNAs have been efficiently expressed in Tet systems without the addition of a Kozak sequence. pTRE-Tight-Gene X plasmids should be cotransfected with the Linear Hygromycin Marker (Cat. No. 631625 is not included) or Linear Puromycin Marker (Cat. No. 631626 is not included) to permit selection of stable transfectants. pTRE-Tight was derived from pTRE, originally described as pUHD10-3 in reference 5.

The pTRE-Tight-Luc Control Vector, packaged with the pTRE-Tight Vector, contains an additional 1,649 bp encoding firefly luciferase inserted into the MCS. This vector can be used as a reporter of induction efficiency using standard luciferase detection reagents. It is not intended as a cloning vector.

(PR073605; published 28 July 2010)



United States/Canada 800.662.2566 Asia Pacific +1.650.919.7300 Europe +33.(0)1.3904.6880 Japan +81.(0)77.543.6116

Clontech Laboratories, Inc. A Takara Bio Company 1290 Terra Bella Ave. Mountain View, CA 94043 Technical Support (US) E-mail: tech@clontech.com www.clontech.com

Location of features

• *P*_{tight}Tet-responsive promoter: 3–318

Tet response element (TRE_{mod}): 3–252

Location of seven tetO 19-mers: 12-30; 48-66; 83-101; 119-137; 155-173; 190-208 & 226-244

Fragment containing $P_{\min CMVA}$: 258–317

TATAA box: 280–286

- Multiple cloning site (MCS): 323-411
- Fragment containing SV40 poly A signal: 406–606
- Fragment containing Col E1 origin of replication: 780–1379
- Ampicillin resistance gene (β-lactamase): 2536–1541

Sequencing primer locations

pTRE-Tight Sequencing Primers: Forward primer (2577–2600): 5'-AGG CGT ATC ACG AGG CCC TTT CGT-3' Reverse primer (683–660): 5'-TAT TAC CGC CTT TGA GTG AGC TGA-3'

Propagation in *E. coli*

- Suitable host strains: DH5 α^{TM} and other general purpose strains.
- Selectable marker: plasmid confers resistance to ampicillin (100 µg/ml) in *E. coli* hosts.
- E. coli replication origin: Col E1

References

- 1. HT1080 Cell Line & pTRE2 Vector (January 1999) Clontechniques XIV(1):23.
- 2. Gossen, M. & Bujard, H. (1992) Proc. Natl. Acad. Sci USA 89:5547-5551.
- 3. Gossen, M., *et al.* (1995) *Science* **268**:1766–1769.
- Kozak, M. (1987) Nucleic Acids Res. 15:8125–8148.
 Resnitzky, D., et al. (1994) Mol. Cell. Biol. 14:1669–1679.

Note:

The vector sequence was compiled from information in the sequence databases, published literature, and other sources, together with partial sequences obtained by Clontech. This vector has not been completely sequenced.

Notice to Purchaser

Clontech products are to be used for research purposes only. They may not be used for any other purpose, including, but not limited to, use in drugs, *in vitro* diagnostic purposes, therapeutics, or in humans. Clontech products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products or to provide a service to third parties without written approval of Clontech Laboratories, Inc.

Use of the Tetracycline controllable expression systems (the "TetTechnology") is covered by a series of patents including U.S. Patent Nos. 5,464,758 and 5,814,618, which are proprietary to TET Systems GmbH & Co. KG. Academic research institutions are granted an automatic license with the purchase of this product to use the TetTechnology only for internal, academic research purposes, which license specifically excludes the right to sell, or otherwise transfer, the TetTechnology or its component parts to third parties. Notwithstanding the above, academic and not-for profit research institutions whose research using the TetTechnology is sponsored by for profit organizations, which shall receive ownership to all data and results stemming from the sponsored research, shall need a commercial license agreement from TET Systems in order to use the TetTechnology. In accepting this license, all users acknowledge that the TetTechnology is experimental in nature. TET Systems GmbH & Co. KG makes no warranties, express or implied or of any kind, and hereby disclaims any warranties, representations, or guarantees of any kind as to the TetTechnology, patents, or products. All others are invited to request a license from TET Systems GmbH & Co. KG prior to purchasing these reagents or using them for any purpose. Clontech is required by its licensing agreement to submit a report of all purchasers of the Tet-controllable expression systems to TET Systems. For license information, please contact: GSF/CEO,TET Systems GmbH & Co. KG,Im Neuenheimer Feld 582,69120 Heidelberg,Germany Tel: +4962215880404 eMail: info@tetsystems.com or use the electronic licensing request form via http://www.tetsystems.com/main_inquiry.htm

 $DH5\alpha^{{}^{\rm TM}}$ is a trademark of LifeTechnologies Corporation.

Clontech, the Clontech logo and all other trademarks are the property of Clontech Laboratories, Inc., unless noted otherwise. Clontech is a Takara Bio Company. ©2010 Clontech Laboratories, Inc.